Pharma Medical News about breast cancer

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Economic evaluation of docetaxel for breast cancer
Expert Opinion in Pharmacotherapy, 01/28/09

Lwin Z et al. - Breast cancer is among the leading causes of cancer morbidity worldwide and accounts for a significant proportion of overall healthcare costs. Cost-effectiveness and cost-utility evaluations of therapy provide insight into the societal value of different treatments, helping decision-makers to prioritize resource allocation and maximize benefit in cancer control within resource constraints. Docetaxel, a plant alkaloid of the taxane group, has been recognized as a highly active chemotherapy agent in breast, lung and prostate cancers, among others.

<< Previous
Inspire Initiates Phase 3 Prolacria Dry Eye Trial under Special...

Next >>
Watsons GELNIQUE (oxybutynin chloride) Gel 10% Approved by FDA...

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09 Relevance Score: 74%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09 Relevance Score: 72%

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09 Relevance Score: 72%

Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09 Relevance Score: 72%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09 Relevance Score: 72%